Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-557-718"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20121023.45.2-557-718"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-557-7502
lpv:speaker	lp:Sergio Paolo Francesco Silvestris2
lpv:spokenAs	substitute; BUDG (2012-01-19--2014-06-30)3 member; AGRI (2012-01-19--2014-06-30)3 substitute; Delegation for relations with Albania, Bosnia and Herzegovina, Serbia, Montenegro and Kosovo (2009-09-16--2014-06-30)3 member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2009-09-16--2014-06-30)3 member_of_the_bureau; EPP (2012-02-03--2014-06-30)3 unknown; Il Popolo della Libertà (2009-07-14--2013-12-11)3 member; Delegation for relations with the Maghreb countries and the Arab Maghreb Union (2009-09-16--2014-06-30)3
lpv:translated text	"The Conformity Assessment and Acceptance of Industrial Products (ACAA) protocol is a technical agreement aiming to facilitate access to the market by removing technical barriers to trade for industrial products. In this particular case the ACAA Protocol between the EU and Israel will apply exclusively to best practice in the manufacturing of pharmaceutical products. I am in favour of negotiating this agreement, which is an element of the Euromed process, the aim of which is to complete and strengthen the network of free trade agreements with all countries in the region. My vote in favour is based on a view of the agreement not as an upgrading of relations between the EU and Israel but rather as a technical agreement provided for in an existing joint document (the EU-Israel Action Plan), falling within the scope of implementation of the Association Agreement and approved by the Council in 2010. This agreement should therefore be seen as based on technical and not political considerations that would simplify reciprocal access to markets for pharmaceutical products, bringing economic benefits for both sides."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph